On October 8, INNOCARE fell 5.11% in regular trading, changing hands at 12.83 HKD with turnover of 68.13 million HKD. The decline came as shareholder stake reductions and a broader biotech sector retreat dampened sentiment.

According to filings, Sunland BioMed Ltd and its concert parties saw their combined interest fall from 7.23% to 6.94%, triggered by a 500,000-share on-market sale on September 30. Separate disclosures showed Jisong Cui and Renbin Zhao also reduced stakes on the same day, each selling 5 million shares, potentially feeding concerns over insider selling pressure.

A prior day's 3.15% drop in the Hang Seng Biotech Index further pressured the stock, with the positive momentum from the up-to-3.35-billion-dollar research deal with Eli Lilly largely priced in, giving room for profit-taking.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)